...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>EBioMedicine >Biomarker concordance between primary colorectal cancer and its metastases
【24h】

Biomarker concordance between primary colorectal cancer and its metastases

机译：原发性大肠癌及其转移之间的生物标志一致性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background The use of biomarkers to target anti-EGFR treatments for metastatic colorectal cancer (CRC) is well-established, requiring molecular analysis of primary or metastatic biopsies. We aim to review concordance between primary CRC and its metastatic sites. Methods A systematic review and meta-analysis of all published studies (1991–2018) reporting on biomarker concordance between primary CRC and its metastatic site(s) was undertaken according to PRISMA guidelines using several medical databases. Studies without matched samples or using peripheral blood for biomarker analysis were excluded. Findings 61 studies including 3565 patient samples were included. Median biomarker concordance for KRAS ( n =?50) was 93.7% [ [67] , [68] , [69] , [70] , [71] , [72] , [73] , [74] , [75] , [76] , [77] , [78] , [79] , [80] , [81] , [82] , [83] , [84] , [85] , [86] , [87] , [88] , [89] , [90] , [91] , [92] , [93] , [94] , [95] , [96] , [97] , [98] , [99] , [100] ], NRAS ( n ?=?11) was 100% [ [90] , [91] , [92] , [93] , [94] , [95] , [96] , [97] , [98] , [99] , [100] ], BRAF ( n ?=?22) was 99.4% [ [80] , [81] , [82] , [83] , [84] , [85] , [86] , [87] , [88] , [89] , [90] , [91] , [92] , [93] , [94] , [95] , [96] , [97] , [98] , [99] , [100] ], and PIK3CA ( n ?=?17) was 93% [ [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] , [52] , [53] , [54] , [55] , [56] , [57] , [58] , [59] , [60] , [61] , [62] , [63] , [64] , [65] , [66] , [67] , [68] , [69] , [70] , [71] , [72] , [73] , [74] , [75] , [76] , [77] , [78] , [79] , [80] , [81] , [82] , [83] , [84] , [85] , [86] , [87] , [88] , [89] , [90] , [91] , [92] , [93] , [94] , [95] , [96] , [97] , [98] , [99] , [100] ]. Meta-analytic pooled discordance was 8% for KRAS (95% CI?=?5–10%), 8% for BRAF (95% CI?=?5–10%), 7% for PIK3CA (95% CI?=?2–13%), and 28% overall (95% CI?=?14–44%). The liver was the most commonly biopsied metastatic site ( n ?=?2276), followed by lung ( n ?=?438), lymph nodes ( n ?=?1123), and peritoneum ( n ?=?132). Median absolute concordance in multiple biomarkers was 81% (5–95%). Interpretation Metastatic CRC demonstrates high concordance across multiple biomarkers, suggesting that molecular testing of either the primary or liver and lung metastasis is adequate. More research on colorectal peritoneal metastases is required.
机译：背景技术使用生物标记物靶向转移性结直肠癌（CRC）的抗EGFR治疗已广为接受，需要对原发性或转移性活检进行分子分析。我们旨在审查原发性结直肠癌及其转移部位之间的一致性。方法根据PRISMA指南，使用多个医学数据库，对所有发表的研究（1991-2018年）报告了原发性CRC及其转移部位之间生物标志物一致性的研究进行了系统的回顾和荟萃分析。没有匹配样品或使用外周血进行生物标记分析的研究被排除在外。结果包括61个研究，包括3565个患者样本。 KRAS（n =？50）的中位生物标记一致性为93.7％[[67]，[68]，[69]，[70]，[71]，[72]，[73]，[74]，[75] ，[76]，[77]，[78]，[79]，[80]，[81]，[82]，[83]，[84]，[85]，[86]，[87]，[ 88]，[89]，[90]，[91]，[92]，[93]，[94]，[95]，[96]，[97]，[98]，[99]，[100] ]，NRAS（n≥11）为100％[[90]，[91]，[92]，[93]，[94]，[95]，[96]，[97]，[98]， [99]，[100]]，BRAF（n = 22）为99.4％[[80]，[81]，[82]，[83]，[84]，[85]，[86]，[ 87]，[88]，[89]，[90]，[91]，[92]，[93]，[94]，[95]，[96]，[97]，[98]，[99] ，[100]]和PIK3CA（n？=？17）为93％[[42]，[43]，[44]，[45]，[46]，[47]，[48]，[49] ，[50]，[51]，[52]，[53]，[54]，[55]，[56]，[57]，[58]，[59]，[60]，[61]，[ 62]，[63]，[64]，[65]，[66]，[67]，[68]，[69]，[70]，[71]，[72]，[73]，[74] ，[75]，[76]，[77]，[78]，[79]，[80]，[81]，[82]，[83]，[84]，[85]，[86]，[ 87]，[88]，[89]，[90]，[91]，[92]，[93]，[94]，[95]，[96]， [97]，[98]，[99]，[100]。荟萃分析发现，KRAS的不一致性为8％（95％CI？=？5-10％），BRAF的8％（95％CI？=？5-10％），PIK3CA的为7％（95％CI？=占2-13％），整体占28％（95％CI等于14-44％）。肝脏是最常见的活检转移部位（n = 2276），其次是肺（n = 438），淋巴结（n = 1123）和腹膜（n = 132）。多种生物标志物的绝对绝对中位数为81％（5-95％）。解释转移性CRC在多种生物标志物之间显示出高度的一致性，这表明对原发或肝，肺转移的分子检测是足够的。需要对结直肠腹膜转移进行更多研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号